New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors

S Faivre, S Djelloul, E Raymond - Seminars in oncology, 2006 - Elsevier
Signal transduction in cancer cells is a sophisticated process that involves receptor tyrosine
kinases (RTKs) that eventually trigger multiple cytoplasmic kinases, which are often …

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

S Faivre, S Djelloul, E Raymond - Seminars in Oncology, 2006 - europepmc.org
Signal transduction in cancer cells is a sophisticated process that involves receptor tyrosine
kinases (RTKs) that eventually trigger multiple cytoplasmic kinases, which are often …

New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors

S Faivre, S Djelloul, E Raymond - Seminars in Oncology, 2006 - infona.pl
Signal transduction in cancer cells is a sophisticated process that involves receptor tyrosine
kinases (RTKs) that eventually trigger multiple cytoplasmic kinases, which are often …

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors

S Faivre, S Djelloul, E Raymond - Seminars in oncology, 2006 - pubmed.ncbi.nlm.nih.gov
Signal transduction in cancer cells is a sophisticated process that involves receptor tyrosine
kinases (RTKs) that eventually trigger multiple cytoplasmic kinases, which are often …

[引用][C] New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors

S FAIVRE, S DJELLOUL… - Seminars in oncology, 2006 - pascal-francis.inist.fr
New paradigms in anticancer therapy : Targeting multiple signaling pathways with kinase
inhibitors CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

[引用][C] New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors

S FAIVRE, S DJELLOUL, E RAYMOND - Seminars in oncology, 2006 - Elsevier